placeholder image
A. L. Naleway Institute former member
About
Publications While At 开云体育
selected publications
Journal Article
  • 18 years - VISION and IVY Networks, September 2024-January 2025. 
    MMWR: Morbidity and Mortality Weekly Report. 2025
  • Influenza-associated hospitalization rates by underlying conditions, 2016-17 to 2019-20: a retrospective cohort study. 
    Journal of Infectious Diseases. 2025
  • Methods to adjust for confounding in test-negative design COVID-19 effectiveness studies: simulation study. 
    JMIR formative research. 2025
  • Patterns in prescribing and dispensing of influenza antivirals among adults with influenza presenting to urgent care and emergency department settings, VISION Network, 2023-2024. 
    Clinical Infectious Diseases. 2025
  • Vaccination during pregnancy in the Vaccine Safety Datalink, 2002-2022. 
    Pediatric Infectious Disease Journal. 2025
  • 18 Years - VISION and IVY Networks, September 2023-January 2024. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 
    Clinical Infectious Diseases. 2024
  • Effectiveness of the original monovalent and bivalent COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters in pregnant persons who were not immunocompromised: VISION Network, June 2022-August 2023. 
    Open forum infectious diseases. 2024
  • Influenza vaccination accuracy among adults: self-report compared with electronic health record data. 
    Vaccine. 2024
  • Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States. 
    Clinical Infectious Diseases. 2024
  • Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 
    Journal of Infectious Diseases. 2024
  • JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States. 
    Infection. 2024
  • Obstetric complications and birth outcomes after antenatal coronavirus disease 2019 (COVID-19) vaccination. 
    Obstetrics and Gynecology. 2024
  • Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 
    Lancet (London, England). 2024
  • Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 
    Influenza and other respiratory viruses. 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 
    Clinical Infectious Diseases. 2024
  • Accuracy of COVID-19-like illness diagnoses in electronic health record data: retrospective cohort study. 
    JMIR formative research. 2023
  • Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. 
    American Journal of Epidemiology. 2023
  • Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 
    Pediatrics. 2023
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 
    Vaccine. 2023
  • Effectiveness of the original monovalent coronavirus disease 2019 vaccines in preventing emergency department or urgent care encounters and hospitalizations among adults with disabilities: VISION Network, June 2021-September 2022. 
    Open forum infectious diseases. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 
    American Journal of Transplantation. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 
    JAMA network open. 2023
  • Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. 
    Vaccine. 2023
  • Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic. 
    Obstetrics and Gynecology. 2023
  • Influenza vaccination among pregnant women: self-report compared with vaccination data from electronic health records, 2018-2020 influenza seasons. 
    Public Health Reports. 2023
  • Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons. 
    Vaccine. 2023
  • Medically attended acute adverse events in pregnant people after coronavirus disease 2019 (COVID-19) booster vaccination. 
    Obstetrics and Gynecology. 2023
  • Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. 
    Lancet Reg Health Am. 2023
  • Patient and epidemiological factors associated with influenza testing in hospitalized adults with acute respiratory illnesses, 2016-2017 to 2019-2020. 
    Open forum infectious diseases. 2023
  • Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance. 
    Journal of Infectious Diseases. 2023
  • Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 
    Journal of Infectious Diseases. 2023
  • Racial and ethnic disparities in influenza vaccination coverage among pregnant women in the United States: the contribution of vaccine-related attitudes. 
    Preventive Medicine. 2023
  • Relationships between social vulnerability and coronavirus disease 2019 vaccination coverage and vaccine effectiveness. 
    Clinical Infectious Diseases. 2023
  • Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. 
    Vaccine. 2023
  • Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes. 
    Vaccine. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 
    Journal of Infectious Diseases. 2023
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 
    American Journal of Transplantation. 2022
  • Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 
    JAMA network open. 2022
  • Evaluation of acute adverse events after Covid-19 vaccination during pregnancy. 
    New England Journal of Medicine. 2022
  • Monitoring vaccine safety using the Vaccine Safety Datalink: assessing capacity to integrate data from Immunization Information systems. 
    Vaccine. 2022
  • Relative risks of COVID-19-associated hospitalizations and clinical outcomes by age and race/ethnicity-March 2020-March 2021. 
    Open forum infectious diseases. 2022
  • Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 
    Vaccine. 2022
  • Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 
    Pediatrics. 2022
  • Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink. 
    Vaccine. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 
    BMJ (Clinical research ed.). 2022
  • Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes. 
    JAMA network open. 2021
  • COVID-19 vaccination coverage among insured persons aged 鈮�16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • COVID-19 vaccination coverage among pregnant women during pregnancy - eight integrated health care organizations, United States, December 14, 2020-May 8, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Developing algorithms for identifying major structural birth defects using automated electronic health data. 
    Pharmacoepidemiology and Drug Safety. 2021
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 
    New England Journal of Medicine. 2021
  • Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. 
    Vaccine. 2021
  • Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June-August 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Spontaneous abortion following COVID-19 vaccination during pregnancy. 
    JAMA. 2021
  • Surveillance for adverse events after COVID-19 mRNA vaccination. 
    JAMA. 2021
  • Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. 
    Therapeutic advances in drug safety. 2021
  • Evaluating the association of stillbirths after maternal vaccination in the Vaccine Safety Datalink. 
    Obstetrics and Gynecology. 2020
  • SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. health care centers, March 1-May 30, 2020. 
    MMWR: Morbidity and Mortality Weekly Report. 2020
  • Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. 
    Vaccine. 2019
  • Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. 
    Vaccine. 2019
  • 2015-2016 Vaccine effectiveness of live attenuated and inactivated influenza vaccines in children in the United States. 
    Clinical Infectious Diseases. 2018
  • Infant hospitalizations and mortality after maternal vaccination. 
    Pediatrics. 2018
  • Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. 
    Obstetrics and Gynecology. 2018
  • The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: a Vaccine Safety Datalink study. 
    Pharmacoepidemiology and Drug Safety. 2018
  • Uptake and safety of Hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study. 
    Vaccine. 2018
  • Febrile seizure risk after vaccination in children one to five months of age. 
    Pediatric Neurology. 2017
  • First trimester influenza vaccination and risks for major structural birth defects in offspring. 
    Journal of Pediatrics. 2017
  • Identifying birth defects in automated data sources in the Vaccine Safety Datalink. 
    Pharmacoepidemiology and Drug Safety. 2017
  • Live attenuated influenza vaccine use and safety in children and adults with asthma. 
    Annals of Allergy, Asthma, and Immunology. 2017
  • Maternal Tdap vaccination and risk of infant morbidity. 
    Vaccine. 2017
  • Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. 
    Obstetrics and Gynecology. 2017
  • Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. 
    BMC Pulmonary Medicine. 2017
  • Febrile seizure risk after vaccination in children 6 to 23 months. 
    Pediatrics. 2016
  • Influenza vaccination during pregnancy: influenza seasons 2002-2012, Vaccine Safety Datalink. 
    American Journal of Preventive Medicine. 2016
  • Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. 
    Vaccine. 2016
  • Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: caveats when conducting retrospective observational studies. 
    American Journal of Epidemiology. 2016
  • Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. 
    JAMA. 2015
  • Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. 
    Vaccine. 2015
  • Safety of measles-containing vaccines in 1-year-old children. 
    Pediatrics. 2015
  • Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. 
    Obstetrics and Gynecology. 2015
  • Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. 
    Pharmacoepidemiology and Drug Safety. 2014
  • Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. 
    JAMA. 2014
  • Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. 
    Vaccine. 2014
  • Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink Sites. 
    Preventive Medicine. 2014
  • Timely versus delayed early childhood vaccination and seizures. 
    Pediatrics. 2014
  • Vaccinations given during pregnancy, 2002-2009: a descriptive study. 
    American Journal of Preventive Medicine. 2014
  • A population-based cohort study of undervaccination in 8 managed care organizations across the United States. 
    JAMA pediatrics. 2013
  • Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. 
    JAMA pediatrics. 2013
  • Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. 
    JAMA pediatrics. 2013
  • Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. 
    Vaccine. 2013
  • Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. 
    Obstetrics and Gynecology. 2013
  • Maternal safety of trivalent inactivated influenza vaccine in pregnant women. 
    Obstetrics and Gynecology. 2013
  • Mortality rates and cause-of-death patterns in a vaccinated population. 
    American Journal of Preventive Medicine. 2013
  • Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. 
    Vaccine. 2013
  • Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010. 
    Pharmacoepidemiology and Drug Safety. 2013
  • Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. 
    Clinical Infectious Diseases. 2013
  • Safety of the yellow fever vaccine: a retrospective study. 
    Journal of Travel Medicine. 2013
  • Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink Project. 
    Vaccine. 2013
  • Trivalent inactivated influenza vaccine and spontaneous abortion. 
    Obstetrics and Gynecology. 2013
  • Vaccination site and risk of local reactions in children 1 through 6 years of age. 
    Pediatrics. 2013
  • Measles-containing vaccines and febrile seizures in children age 4 to 6 years. 
    Pediatrics. 2012
  • Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. 
    Influenza and other respiratory viruses. 2012
  • H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. 
    American Journal of Preventive Medicine. 2011
  • Injection site and risk of medically attended local reactions to acellular pertussis vaccine. 
    Pediatrics. 2011
  • Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. 
    Vaccine. 2011
  • Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. 
    Archives of Pediatrics and Adolescent Medicine. 2011
  • Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. 
    Pediatrics. 2010
  • Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study. 
    BMC Infectious Diseases. 2009
  • Risk of immune hemolytic anemia in children following immunization. 
    Vaccine. 2009
  • Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. 
    Vaccine. 2009
  • Varicella vaccination and ischemic stroke in children: is there an association?. 
    Pediatrics. 2009
  • Incidence of neonatal herpes simplex virus infections in two managed care organizations: implications for surveillance. 
    Sexually Transmitted Diseases. 2008
    • Conference Poster
  • Acute adverse events following trivalent inactivated influenza vaccine (TIV) in pregnancy [poster]
    2012
  • Estimating pregnancy start dates with prenatal procedure codes [poster]
    2011
  • Safety of seasonal influenza vaccine (TIV) in pregnant women [poster]
    2011
  • Safety of the yellow fever vaccine: a retrospective study [poster]
    2011
  • Comparison of neonatal HSV (herpes simplex virus) risk factors in cesarean and vaginal deliveries [poster]
    2008
    • Review
  • The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety [review]. 
    Vaccine. 2014
  • Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink [review]. 
    American Journal of Obstetrics and Gynecology. 2012
    • Abstract
  • A descriptive study of vaccinations occurring during pregnancy, 2002-2006 [abstract]. 
    Clinical Medicine & Research. 2012
  • Identifying pregnancy episodes in the Vaccine Safety Datalink [abstract]. 
    Clinical Medicine & Research. 2012
    • presentations
    Contact
    full name
  • A. L. Naleway
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration